Goldline Pharmaceutical Limited Peer Comparison
The Goldline Pharmaceutical IPO is a book build issue with a total issue size of ₹12 cr, comprising of fresh issue of 2562000 equity shares. Goldline Pharmaceutical IPO opened for subscription on May 12, 2026 and closed on May 14, 2026. Goldline Pharmaceutical IPO is set price band at ₹41 to ₹43 per share, with a lot size of 3000 shares. Minimum investment for Retail investors was ₹258,000.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on May 15, 2026, and listed on both the NSE and BSE on May 19, 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar. Cumulative Capital Private Limited are the Book Running Lead Manager for the issue.
Before investing in the Goldline Pharmaceutical IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Goldline Pharmaceutical Limited Peer Comparision
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Ltd | 10 | 0.00 | 4.10 | 4.10 | 27.37 | 12.38 |
| Mono Pharmacare Ltd | 10 | 7.57 | 1.75 | 1.75 | 9.90 | 17.66 |
| Chandra Bhagat Pharma Ltd | 10 | 28.94 | 1.14 | 1.14 | 2.86 | 39.72 |
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Goldline Pharmaceutical IPO is a Book-building IPO with a total issue size of ₹12 crore. The Goldline Pharmaceutical IPO price band is ₹41 to 43 per share. The Goldline Pharmaceutical IPO subscription opens on Tue, May 12, 2026, and closes on Thu, May 14, 2026. The Goldline Pharmaceutical IPO will be listed on the BSE. Bigshare Services Pvt Ltd is the registrar for the Goldline Pharmaceutical IPO.
The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026
Goldline Pharmaceutical IPO Price Band is ₹41 to 43 per share.
Goldline Pharmaceutical IPO lot size is 3000 shares, Retail investors need a minimum investment of ₹258000 based on the upper price band
The minimum investment for Goldline Pharmaceutical IPO is ₹258000, based on one lot of 3000 shares at the upper price band of ₹43 per share.
Investors can apply for the Goldline Pharmaceutical IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, May 14, 2026. The application amount remains blocked until the Goldline Pharmaceutical IPO allotment is finalized.
Goldline Pharmaceutical IPO issue size is ₹12 crores.
Goldline Pharmaceutical IPO allotment date is Wed, Jul 1, 2026.
The registrar for Goldline Pharmaceutical IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Goldline Pharmaceutical IPO allotment status, refund processing, and other IPO-related information.
The Goldline Pharmaceutical IPO GMP (Grey Market Premium) is ₹15 as of Tue, May 19, 2026. Based on the upper price band of ₹43 per share, the estimated Goldline Pharmaceutical IPO listing price is ₹58, indicating a potential listing gain of approximately 0% over the issue price.